EuroPCR 2023 |TAVR in Cardiogenic Shock

Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear.

The aim of this study was to assess events in patients undergoing TAVR with balloon expandable valves (SAPIEN 3 and SAPIEN 3 Ultra). 

Populations were matched with propensity score. Primary end point was inhospital all-cause mortality, at 30 days and one year, and major complications in the same period of time. 

Data from 4952 patients with cardiogenic shock were obtained. Mean age was 75.6 year with mean ejection fraction of 39.9%. observed complications were annulus rupture in 0.3%, aortic dissection in 0.2%, 0.4% coronary obstruction, 1% cardiac perforation, 0.2% devise embolization and 0.7% conversion to open surgery. 

Compared against the matched cohort with no cardiogenic shock, there was more inhospital mortality (9.9% vs 2.7%, P<0.0001), stroke (2.9% vs 1.5%; P<0.0001), vascular complications (2.3% vs 1.3%, P<0.0001) and major bleeding (2.5% vs 0.7%, P<0.0001). 

At one year, were was 29.7% mortality vs 22.6% in patients with no cardiogenic shock (HR 1.57, CI 95% 1.43-1.72, P<0.001). After multivariable analysis, predictors of mortality at 30 days were dialysis, pacemaker implantation, assisting device requirement, and peripheral vascular disease. 

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

The author concluded that TAVR was effective and safe in the context of cardiogenic shock with acceptable events at 30 days and one year. These outcomes observed in a registry should suggest “primary” TAVR as the best strategy for patients with aortic stenosis leading to cardiogenic shock. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Abhijeet Dhoble at Late Breaking Trials Sessions, EuroPCR 2023, May 16, 2023, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....